

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

MDA-MB-134-VI

RRID:CVCL_0617

Type: Cell Line

Proper Citation

RRID:CVCL_0617

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0617

Proper Citation: RRID:CVCL_0617

Description: Cell line MDA-MB-134-VI is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Invasive breast lobular carcinoma

Defining Citation: [PMID:730202](#), [PMID:833871](#), [PMID:3518877](#), [PMID:4412247](#), [PMID:6220172](#), [PMID:7842014](#), [PMID:9331070](#), [PMID:9671407](#), [PMID:10862037](#), [PMID:10969801](#), [PMID:11044355](#), [PMID:11343771](#), [PMID:12353263](#), [PMID:12800145](#), [PMID:15677628](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:24425047](#), [PMID:25485619](#), [PMID:25757734](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:28889351](#), [PMID:30228172](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: FGFR genetic alteration cell panel (ATCC TCP-1034)., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-MB-134-VI

Synonyms: MDA-MB-134 VI, MDA MB 134VI, MDA-MB-134VI, MDAMB134VI, MDA-MB-134, MDAMB134, MDA-134, MDA134, MM134, MD Anderson-Metastatic Breast-134-VI

Cross References: CLO:CLO_0007631, EFO:EFO_0001205, CLDB:cl3398, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ATCC:HTB-23, BioSample:SAMN03471473, BioSample:SAMN10988465, cancercellines:CVCL_0617, CCRID:1101HUM-PUMC000380, Cell_Model_Passport:SIDM00005, ChEMBL-Cells:ChEMBL3308340, ChEMBL-Targets:ChEMBL2366242, Cosmic:687491, Cosmic:735125, Cosmic:809233, Cosmic:904374, Cosmic:908119, Cosmic:934525, Cosmic:997933, Cosmic:1000129, Cosmic:1046947, Cosmic:1047696, Cosmic:1090333, Cosmic:1136347, Cosmic:1152519, Cosmic:1287908, Cosmic:1289392, Cosmic:1603216, DepMap:ACH-000044, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:908119, GEO:GSM115107, GEO:GSM186432, GEO:GSM186433, GEO:GSM186434, GEO:GSM217584, GEO:GSM219959, GEO:GSM320180, GEO:GSM350523, GEO:GSM421870, GEO:GSM783960, GEO:GSM847398, GEO:GSM847491, GEO:GSM887292, GEO:GSM888367, GEO:GSM1053695, GEO:GSM1172886, GEO:GSM1172976, GEO:GSM1215268, GEO:GSM1226522, GEO:GSM1226523, GEO:GSM1226524, GEO:GSM1226525, GEO:GSM1226526, GEO:GSM1226527, GEO:GSM1226528, GEO:GSM1226529, GEO:GSM1226530, GEO:GSM1226531, GEO:GSM1226532, GEO:GSM1226533, GEO:GSM1226534, GEO:GSM1226535, GEO:GSM1226536, GEO:GSM1226537, GEO:GSM1226538, GEO:GSM1226539, GEO:GSM1226540, GEO:GSM1226541, GEO:GSM1238133, GEO:GSM1374647, GEO:GSM1401662, GEO:GSM1661981, GEO:GSM1670078, IARC_TP53:18375, IZSLER:BS TCL 236, LiGeA:CCLE_784, LINCS_HMS:50327, LINCS_LDP:LCL-1316, PharmacoDB:MDAMB134VI_897_2019, Progenetix:CVCL_0617, PubChem_Cell_line:CVCL_0617, SLKBase:3582, Wikidata:Q54904577

ID: CVCL_0617

Record Creation Time: 20220427T220755+0000

Record Last Update: 20260829T234601+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-134-VI.

No alerts have been found for MDA-MB-134-VI.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sottnik JL, et al. (2026) Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. Cancer research, 86(7),

Sottnik JL, et al. (2026) Advanced models of lobular breast cancer metastasis capture clinical organ tropism, endocrine response, and bone remodeling. *bioRxiv : the preprint server for biology*.

Flaherty RL, et al. (2026) LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma. *Cancer research*, 86(10), 2487.

Liu S, et al. (2026) RET signaling as a mediator of estrogen receptor positive breast cancer brain metastasis. *Communications biology*.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. *Cell reports. Medicine*, 7(7), 102922.

Zhou W, et al. (2026) Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers. *Cell chemical biology*, 33(6), 785.

Gonzalez-Ericsson PI, et al. (2025) Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(17), 3652.

Sottnik JL, et al. (2024) WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers. *Cancer research communications*, 4(1), 134.

Young TA, et al. (2024) Glutamate Transport Proteins and Metabolic Enzymes are Poor Prognostic Factors in Invasive Lobular Carcinoma. *bioRxiv : the preprint server for biology*.

Yates ME, et al. (2024) ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes. *Endocrinology*, 165(10).

Yates ME, et al. (2023) ESR1 fusion proteins invoke breast cancer subtype-dependent enrichment of ligand independent pro-oncogenic signatures and phenotypes. *bioRxiv : the preprint server for biology*.

Olukoya AO, et al. (2023) Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer. *Journal of the Endocrine Society*, 7(10), bvad117.

Elangovan A, et al. (2022) Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma. *Molecular cancer research : MCR*, 20(9), 1405.

Sottnik JL, et al. (2021) Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast. *Molecular cancer research : MCR*, 19(8), 1270.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. *Cell systems*, 12(5), 401.

Chen F, et al. (2021) Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells. *Cancer research*, 81(2), 268.

Cotul EK, et al. (2020) Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers. *Cancers*, 12(9).

Mabe NW, et al. (2020) G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program. *Cell reports*, 33(5), 108341.

Sreekumar S, et al. (2020) Differential Regulation and Targeting of Estrogen Receptor ?? Turnover in Invasive Lobular Breast Carcinoma. *Endocrinology*, 161(9).

Koundouros N, et al. (2020) Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids. *Cell*, 181(7), 1596.